Premium
Infantile haemangioma: Part II. Risks, complications and treatment
Author(s) -
LéautéLabrèze C.,
Prey S.,
Ezzedine K.
Publication year - 2011
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.2011.04105.x
Subject(s) - medicine , involution (esoterism) , disfigurement , infantile hemangioma , propranolol , intensive care medicine , telangiectasia , treatment modality , surgery , pediatrics , politics , political science , law
Because of their spontaneous involution, most infantile haemangiomas (IH) do not require therapeutic intervention. However, in 10 to 15% of cases such as segmental and multifocal IH, locations in the periocular, airway and perineal areas, or complications of ulceration, treatment is necessary. Moreover, the risk of permanent scarring and disfigurement associated with IH, even if involution is complete, has been increasingly recognized as a rationale for treatment. Treatments for IH currently include topical, intralesional, systemic therapies, laser and surgical modalities depending on the clinical scenario. However, clinicians must carefully weigh the risks and benefits for each treatment. Recently, the efficacy of propranolol, a non‐cardioselective beta‐blocker, was reported and has been revolutionary in the management of IH.